Company Filing History:
Years Active: 1999-2000
Title: The Innovations of Jeffrey A. Leiby
Introduction
Jeffrey A. Leiby is a notable inventor based in Kalamazoo, MI (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target dopamine receptors. With a total of 3 patents to his name, his work has implications for treating central nervous system disorders.
Latest Patents
Leiby's latest patents include innovative compounds such as phenylsulfonamide-phenylethylamines, which are useful as dopamine receptor agents. These compounds, represented by Formula I, have selective dopamine D3 receptor activity that is suitable for treating various central nervous system disorders. Another significant patent involves aryl substituted bicyclic amines, which also serve as selective dopamine D3 ligands, further contributing to the treatment of disorders associated with dopamine D3 receptor activity.
Career Highlights
Jeffrey A. Leiby has been associated with Pharmacia & Upjohn Company, where he has focused on research and development in the pharmaceutical sector. His work has been instrumental in advancing the understanding and treatment of conditions related to dopamine receptor activity.
Collaborations
Throughout his career, Leiby has collaborated with esteemed colleagues such as Arthur Glenn Romero and William H. Darlington. These partnerships have fostered a collaborative environment that enhances innovation and research in their field.
Conclusion
Jeffrey A. Leiby stands out as a significant figure in pharmaceutical innovation, with a focus on developing compounds that address critical health issues. His contributions continue to impact the treatment of central nervous system disorders, showcasing the importance of research and collaboration in the field of medicine.